UroGen Pharma Ltd. — Director's Dealing 2022

Mar 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-03-25

Reporting Person: Kim Dong (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-25	Employee Stock Option (right to buy)	$8.61	A	30000	Acquired	2032-03-24	Ordinary Shares (30000)	Direct

Footnotes

F1: One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.